EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Changes in evidence used for FDA Novel Drug Approvals: 2016-2024

Aditya Narayan iD, Veronica L Irvin, Amanda J Koong iD, Sujin Song iD, Robert M Kaplan

PLOS One · 2026

DOI: 10.1371/journal.pone.0342878 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Aditya Narayan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University School of Medicine, Clinical Excellence Research Center, Palo Alto, California, United States of America. Hauptthemen laut MEDLINE: Drug Approval, United States Food and Drug Administration. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 21st Century Cures Act (2017) was enacted during a period of evolving FDA flexibility in evidentiary standards for drug approval. To examine trends before and after implementation, we independently reviewed all novel drugs approved between 2016 and 2024.

Methods

We constructed a database of all novel FDA approvals from January 1, 2016, through December 31, 2024. Each study linked to an approved drug (N = 6,763) was cataloged by study number, sponsorship, and timing of results reporting relative to completion.

Results

Since 2016, the number of studies supporting approval has steadily declined. Beginning in 2017, the modal number of studies per approval fell to one. Industry sponsorship increased while NIH-supported studies decreased. Average time to public posting of results exceeded the one-year statutory limit.

Conclusions

In the post-2016 period, FDA approvals were supported by fewer studies and by a greater proportion of industry-sponsored studies. Although this may accelerate access to new therapies, it raises concerns about the strength of evidence for safety and effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalUnited States Food and Drug AdministrationUnited StatesHumansDrug IndustryDatabases, Factual

Autor:innen und Institutionen

  • Stanford University School of Medicine, Clinical Excellence Research Center, Palo Alto, California, United States of America.
  • Stanford University Graduate School of Business, Palo Alto, California United States of America.
  • Oregon State University, College of Health, Corvallis, Oregon, United States of America.
  • McGovern School of Medicine, Houston, Texas, USA and UCLA, Fielding School of Public Health, Los Angeles, California, United States of America.

ORCID-Profile: Aditya Narayan, Amanda J Koong, Sujin Song

Zitieren

APA

Narayan, A., Irvin, V. L., Koong, A. J., Song, S., & Kaplan, R. M. (2026). Changes in evidence used for FDA Novel Drug Approvals: 2016-2024. PLOS One. https://doi.org/10.1371/journal.pone.0342878

Vancouver

Narayan A, Irvin VL, Koong AJ, Song S, Kaplan RM. Changes in evidence used for FDA Novel Drug Approvals: 2016-2024. PLOS One. 2026. doi:10.1371/journal.pone.0342878

BibTeX
@article{Narayan2026,
  author = {Narayan, Aditya and Irvin, Veronica L and Koong, Amanda J and Song, Sujin and Kaplan, Robert M},
  title = {Changes in evidence used for FDA Novel Drug Approvals: 2016-2024},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0342878}
}
Kostenlos starten →